Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05781360 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
A Phase 1 study, sponsored by Jiangsu Simcere Pharmaceutical Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT05781360 is a Phase 1 study that was terminated before completion, run by Jiangsu Simcere Pharmaceutical Co.. The registered enrollment target is 192 participants.
The verdict
NCT05781360, a Phase 1 study, was terminated before completion, sponsored by Jiangsu Simcere Pharmaceutical Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, phase I study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic(PD) characteristics of SIM0237 in participants with advanced solid tumors.
Interventions
- DRUG SIM0237
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2024-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05781360
The ClinicalTrials.gov registry entry for NCT05781360 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jiangsu Simcere Pharmaceutical Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SIM0237 is the first listed.
NCT05781360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05781360 about?
NCT05781360 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors". This is a multicenter, open-label, phase I study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic(PD) characteristics of SIM0237 in participants with advanced solid tumors.
What is the current status of trial NCT05781360?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2023-03-08. Estimated completion is 2024-05-25.
What interventions are being tested in trial NCT05781360?
The interventions under investigation include: SIM0237 (DRUG).
Who is sponsoring clinical trial NCT05781360?
This trial is sponsored by Jiangsu Simcere Pharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.